SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

Me still merchandises its ancestry, health analysis, and the Total Health annual package on a scale from $99 to $999 annually. Lemonaid entered the hot GLP-1 prescribing and support business in 2024, ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations. A ...

23andMe Holding Co. has introduced Discover23®, a new research platform allowing authorized partners to securely access a vast array of genetic data through a Trusted Research Environment (TRE ...

SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research ...

23andMe (ME) Holding announced the launch of Discover23, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through ...